Search
JBPOS0101
go.drugbank.com/drugs/DB16034InvestigationalJBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersNafithromycin
go.drugbank.com/drugs/DB16246InvestigationalNafithromycin is under investigation in clinical trial NCT02903836 (Phase II Study of Oral Nafithromycin in CABP).
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsOsalmid
go.drugbank.com/drugs/DB16273InvestigationalOsalmid is under investigation in clinical trial NCT03670173 (Safety and Efficacy Assessments of Osalmid in Multiple Myeloma).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesToralizumab
go.drugbank.com/drugs/DB16384InvestigationalToralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
Vitis vinifera seed
go.drugbank.com/drugs/DB16606InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsEladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigationalEladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder. … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.